Tevogen Bio Holdings Inc.
TVGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TVGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TVGN
Tevogen Bio Holdings Inc. is a pre-revenue biotechnology company focused on developing T-cell-based immunotherapies, primarily its lead candidate TVGN 489, and relies on external funding to support its operations and clinical development plans.
Key risk: Negative equity and losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Tevogen Bio Holdings Inc..
Tevogen Bio Holdings Inc. is a pre-revenue biotechnology company focused on developing T-cell-based immunotherapies, primarily its lead candidate TVGN 489, and relies on external funding to support its operations and clinical development plans.
- Lead product candidate is TVGN 489, an investigational T-cell immunotherapy [sec_mda · as of 2026-08-14].
- Cash and equivalents were $1.1 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net loss for the quarter ended June 30, 2026 was $5.8 million [sec].
- Shareholders' equity was negative $9.5 million as of June 30, 2026 [sec].
- Total debt was $1.7 million as of June 30, 2026 [sec].
What works
- The company believes its internally developed patents have significant value as the basis of its product pipeline [sec_mda · as of 2026-08-14].
- Tevogen has access to an $11.0 million Loan Agreement and a remaining $7.0 million grant commitment from KRHP, which management believes will provide adequate cash for at least the next 12 months [sec_mda · as of 2026-08-14].
What to weigh
- The company has a history of losses and negative cash flows since commencing operations in June 2020, with an accumulated deficit and negative shareholders' equity of $9.5 million as of June 30, 2026 [sec].
- Tevogen will need additional funding to fully implement its business plans, including commercialization expenses and clinical trials [sec_mda · as of 2026-08-14].
- The company faces significant uncertainty regarding the progress, costs, and results of its planned clinical trials for TVGN 489 [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash of approximately $1.1 million.”
SEC MD&A · August 14, 2026
Need for additional funding
“we will need additional funding to fully implement our business plans.”
SEC MD&A · August 14, 2026
Patent value belief
“We believe these patents have significant value as the basis of our product pipeline.”
SEC MD&A · August 14, 2026
Cash runway assessment
“We believe that our cash balance, the $11.0 million available under the Loan Agreement, and the remaining commitment for a $7.0 million grant from KRHP will allow us to have adequate cash and financial resources to operate for at least the next 12 months”
SEC MD&A · August 14, 2026
Risks & what to watch (3)›
Key risks
- Negative equity and losses — Shareholders' equity was negative $9.5 million as of June 30, 2026, reflecting accumulated losses since inception [sec].
- Dependence on external funding — The company requires additional funding to execute its business plan, including clinical trials and commercialization [sec_mda · as of 2026-08-14].
- Clinical development uncertainty — The progress, costs, and results of planned clinical trials for TVGN 489 are uncertain and could materially affect the company [sec_mda · as of 2026-08-14].
What to watch
- Progress and results of planned clinical trials for TVGN 489 [sec_mda · as of 2026-08-14].
- Ability to secure additional funding beyond the current loan and grant commitments [sec_mda · as of 2026-08-14].
- Changes in cash position and burn rate in upcoming quarterly filings [sec].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Tevogen Bio Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tevogen Bio Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
1.4 months
OCF -$3M · Net income -$6M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$722K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 66,496 | $301K |
| blackrock, inc. | 24,395 | $110K |
| morgan stanley | 17,334 | $78K |
| geode capital management, llc | 15,734 | $71K |
| deutsche bank ag\ | 15,324 | $69K |
| fmr llc | 10,157 | $46K |
| vanguard portfolio management llc | 4,525 | $20K |
| vanguard fiduciary trust co | 1,368 | $6K |
| rhumbline advisers | 1,003 | $5K |
| tower research capital llc (trc) | 941 | $4K |
Showing top 10 of 28 institutional holders of Tevogen Bio Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 8.4%
- Days to cover
- 2.2
- Shares short
- 111,863
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TVGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tevogen Bio Holdings Inc.?
Tevogen Bio Holdings Inc. is a pre-revenue biotechnology company focused on developing T-cell-based immunotherapies, primarily its lead candidate TVGN 489, and relies on external funding to support its operations and clinical development plans.
What is Tevogen Bio Holdings Inc.'s lead drug candidate?
Tevogen Bio Holdings Inc.'s most advanced tracked candidate is tvgn 489 (Phase 1) for COVID-19 and Long COVID.
Who is the CEO of Tevogen Bio Holdings Inc.?
Dr. Ryan H. Saadi M.D., M.P.H. is the chief executive officer of Tevogen Bio Holdings Inc. (TVGN).
Where is Tevogen Bio Holdings Inc. headquartered?
Tevogen Bio Holdings Inc. (TVGN) is headquartered in Warren, NJ, United States.
What therapeutic areas does Tevogen Bio Holdings Inc. focus on?
Tevogen Bio Holdings Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.